A research note from Jarden has valued NZX-listed biotech Pacific Edge at double its current share price, citing the long-term commercial potential of its bladder cancer diagnostic technology, just need access to read full article - https://www.facebook.com/NBROnline/
- Forums
- ASX - By Stock
- Analysts pick Pacific Edge to double in value
PEB
pacific edge limited
Add to My Watchlist
1.96%
!
10.4¢

A research note from Jarden has valued NZX-listed biotech...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
10.4¢ |
Change
0.002(1.96%) |
Mkt cap ! n/a |
Open | High | Low | Value | Volume |
10.4¢ | 10.6¢ | 10.4¢ | $20.03K | 191.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
0 | 962 | 10.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.5¢ | 10802 | 0 |
Last trade - 12.44pm 08/08/2025 (20 minute delay) ? |
Featured News
PEB (NZSX) Chart |